Key Takeaways
- Steady quarter, execution on track: Total income grew 15.2% YoY with volume up 9.9% and ARPOB up 11.7%, while the Dombivli hospital opened ahead of schedule.
- Dombivli is the near-term swing factor: The 500-bed greenfield opened in February 2026, months early and on budget; management is confident of a year 2 breakeven but declined to share early occupancy data.
- ARPOB got a one-time insurance bump: ARPOB jumped from ~₹60,600 to ₹67,600, partly from Indore's maturing case mix and partly from biennial insurance renewals that concentrate price increases in a single period.
- The pipeline is fully funded: All announced greenfield projects (Pune South, Mira Road, BKC, Thane expansion) will be covered by internal accruals plus debt kept under 3x EBITDA over the next 4-5 years.
- What to watch next quarter: First meaningful occupancy and revenue numbers from Dombivli, progress on Thane expansion approvals, and whether Indore's ramp-up pace holds.
Dombivli: The Next Growth Engine
- Opened ahead of schedule: The hospital was inaugurated in February 2026, beating the original Q1 FY27 target. The team built 750,000 sq ft, the superstructure for 500 beds, and fit-outs for ~300 beds in just over 24 months.
- Breakeven conviction: Management is confident of achieving breakeven by the end of year 2 of operations, which points to calendar year-end 2027 or 2028. Accreditation and insurance empanelment are underway and expected within 6 to 12 months.
- Early data withheld: Management declined to share occupancy or revenue contribution, calling it "still very early days" and promising a meaningful discussion "in a quarter or 2." Investors have no near-term visibility into the ramp trajectory.
Thakker: "We built 750,000 square feet, the entire superstructure for 500 beds and completed fit outs for approximately 300 beds, all in just over 24 months. And we did it without any cost escalations on time, on budget, no surprises."
Unit-Level Dynamics
| Unit | Occupancy | Growth Drivers |
|---|---|---|
| Thane | ~75% | Mature asset; inflation-linked growth expected at current capacity. |
| Pune | ~65% | Headroom for occupancy growth plus inflation-linked pricing. |
| Indore | 45–50% | All three levers active: occupancy ramp, case-mix improvement, and inflation. Added capacity last year still absorbing; near-maturity expected in 2–3 years. |
- Indore's dual tailwind: The unit is still filling beds added last year while simultaneously improving its case mix, a combination that should drive ARPOB and margins over the next 1–2 years. Phase 2 expansion (111 beds) will be considered only once occupancy crosses 60%.
- Thane expansion pending: Approval processes are underway with some interim nods received, but management refused to predict a timeline, citing unpredictable regulatory processes. Final approvals are expected sometime this financial year.
- No unit-wise ARPOB disclosed: Management provided occupancy figures but did not break out ARPOB by unit for the full year, limiting visibility into the mix effect.
ARPOB & Revenue Mix
- The insurance renewal bump: ARPOB rose from ~₹60,600 to ₹67,600, driven by Indore's improving case mix and insurance renewals that happen once every two years. These renewals concentrate price increases into a single period, so the jump is partly structural and partly lumpy.
- Insurance now dominates the payer mix: Insurance contributed 55.4% of revenue in Q4, while government schemes accounted for just 1%. The rolling nature of insurance renewals means there is no single seasonal month for renegotiations.
- Medical tourism is not a lever: Management explicitly declined to pursue international patients, stating the model is built around local residential communities within a 45-minute drive. The segment is not margin-accretive enough to justify focus, and local demand is sufficient.
The Greenfield Pipeline
- Pune South: On track to open in calendar year 2028.
- Mira Road: Architectural drawings are complete; regulatory clearances are underway; excavation is expected to begin by the end of this year.
- BKC: A 400-bed quaternary care hospital on over 1 lakh sq ft of land in Mumbai's most prominent commercial district. Management frames it as a declaration of intent to compete at the highest level. 25% of the land cost has been paid; remaining payment due this financial year; detailed project cost calculations await final regulatory clearances and scope definition.
- Funding math holds: All projects will be funded through internal accruals over 4–5 years, supplemented by debt kept under 3x EBITDA. BKC's specific funding structure will be finalized after clearances come through.
Thakker: "BKC is one of the most prominent addresses in the country. Putting up a 400-bed quaternary care hospital on over 1 lakh square feet of land there, is not just another hospital. It's a declaration that Jupiter is ready to compete at the very highest levels in India's most consequential health care market."
Costs & Risks
- Currency and capex costs: The depreciating rupee and the cost of capital equipment are flagged as the key cost concerns, a reality shared across the industry. Doctor costs are not a worry. Some consumables are linked to global supply chains but have not been meaningfully impacted yet.
- Greenfield execution risk is real but managed: Every project in the pipeline is a greenfield, full-scale hub, not a spoke or satellite. The Dombivli delivery, on time and on budget with no cost escalations, serves as proof of execution capability, but each new site carries its own regulatory and ramp-up risk.
Thakker: "We are not trying to just grow fast. We are trying to grow right. Every project in our pipeline is greenfield. Each one is designed as a full-scale hub, not a spoke, not a satellite, but a flagship facility in its own right."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Dombivli breakeven | Achieve breakeven at the hospital level | End of year 2 of operations (calendar year-end 2027/2028) |
| Dombivli accreditation & insurance | NABH accreditation and insurance empanelment completed | Within 6–12 months |
| Pune South opening | Hospital operational | Calendar year 2028 |
| Mira Road construction start | Excavation begins | By end of this year |
| BKC land payment | Remaining 75% of land cost paid | This financial year |
| Thane expansion approvals | Final regulatory approvals received | Sometime this financial year |
| Indore Phase 2 trigger | 111-bed expansion considered | When occupancy crosses or nears 60% |
| Leverage ceiling | Debt kept under 3x EBITDA to fund all announced projects | Over next 4–5 years |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Total income (FY26) | ₹1,499.8 cr, up 15.2% YoY |
| Q4 revenue | ₹387.8 cr, up 15.1% |
| EBITDA (FY26) | ₹343.3 cr, up 14.4% YoY, margin 22.9% |
| Q4 EBITDA | ₹89.2 cr, margin 23% |
| PAT (FY26) | ₹194.2 cr |
| Q4 PAT | ₹50.2 cr, up 11.5% |
| ARPOB | ₹67,700, up 11.7% |
| ALOS | 3.87 days |
| Bed occupancy (3 pre-existing hospitals) | 61.2% |
| Overall volumes | 10.8 lakhs, up 9.9% |
| Insurance revenue mix | 55.4% of revenue; government at 1% |
| Thane occupancy | ~75% |
| Pune occupancy | close to 65% |
| Indore occupancy | between 45% and 50% |
| Dombivli Q4 revenue contribution | ₹9.4 cr |
| Dombivli EBITDA burn | ₹2 cr to ₹3 cr per month on average for the full year |
| Capex deployed in FY26 | ~₹500 cr |
| Gross debt | ~₹500 cr; cash on hand ~₹545 cr |
| Expansion cycle new beds | 1,700 beds at average cost of ~₹1.5 cr per bed; long-term capacity target nearly 3,000 beds |
| BKC land payment | 25% of land cost paid; remaining to be paid in this financial year |